SCHEMBL9974196

SCHEMBL9974196

CCCCC(C(=O)/C=C/c1ccc(OC)c(OC)c1)C(=O)/C=C/c1ccc(OC)c(OC)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APP P05067 2/20 0.61
NFE2L2 Q16236 1/20 0.59
KDM4E B2RXH2 3/20 0.57
ALDH1A1 P00352 1/20 0.57
HPGD P15428 1/20 0.57
ALOX15 P16050 1/20 0.57
MAPK1 P28482 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TOP2A P11388 2/20 0.57
PTGES O14684 1/20 0.56
KMT2A Q03164 2/20 0.55
ABCG2 Q9UNQ0 2/20 0.55
MEN1 O00255 1/20 0.55
BCHE P06276 1/20 0.52
MAOA P21397 1/20 0.52
ACHE P22303 1/20 0.52
MAOB P27338 1/20 0.52
FDPS P14324 3/20 0.51
LMNA P02545 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18079046 0.96 APP (0.60) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL9974198 0.95 TOP2A (0.61) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL9974158 0.86 NFE2L2 (0.62) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL16621560 0.86 APP (0.47) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL9974139 0.86 NFE2L2 (0.66) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL18569889 0.85 NFE2L2 (0.61) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL16621582 0.84 NFE2L2 (0.59) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL9974199 0.84 ALDH1A1 (0.65) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL16888010 0.83 TOP2A (0.47) APPNFE2L2KDM4EALDH1A1HPGD
SCHEMBL18570134 0.83 NFE2L2 (0.62) APPNFE2L2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2993165-B1 COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF ALLIANZ PHARMASCIENCE LTD (TW) 2018-06-27 EP disclosed
EP-2993165-A2 COMPOUNDS WITH (SUBSTITUTED PHENYL)-PROPENAL MOIETY, THEIR DERIVATIVES, BIOLOGICAL ACTIVITY, AND USE THEREOF Allianz Pharmascience Ltd (TW) 2016-03-09 EP disclosed
US-8202905-B2 Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof ANDROSCIENCE CORPORATION (US) 2012-06-19 US disclosed
US-20100292342-A1 Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof Annji Pharmaceutical Co., Ltd. (TW) 2010-11-18 US disclosed
US-20090035362-A1 Compositions including androgen receptor degradation (ARD) enhancers and methods of prophylactic or therapeutic treatment of skin disorders and hair loss ANDROSCIENCE CORPORATION 2009-02-05 US disclosed
US-20080188557-A1 Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof Annji Pharmaceutical Co., Ltd. (TW) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292342-A1 Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof AR, CYP17A1, CYP19A1 APP 964/4885NFE2L2 73/4885KDM4E 484/4885
US-20080188557-A1 Compounds with (substituted phenyl)-propenal moiety, their derivatives, biological activity, and use thereof AR, CYP17A1, CYP19A1 APP 964/4885NFE2L2 73/4885KDM4E 484/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.